ArticleTranslational cancer research2025
Microbial community profiles in breast cancer and normal adjacent tissues: associations with clinicopathological characteristics.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Host-microbiome interactions in breast cancer progression and treatment response.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The microorganisms in breast tissue and its surrounding environment play a critical role in the development and progression of breast cancer (BC). This study aims to characterize BC-associated microbiota via 16S ribosomal RNA (rRNA) sequencing to explore potential pathogenic mechanisms and support early diagnosis and personalized treatment. Methods: Tumor and normal adjacent tissue (NAT) samples from 31 BC patients were analyzed by 16S rRNA sequencing targeting five variable regions. Microbial composition was analyzed via the Short MUltiple Regions Framework (SMURF) pipeline. Alpha and beta diversity analyses were conducted to compare the microbial communities between the BC and NAT groups, and among different BC subgroups stratified by the molecular subtype, clinical stage, histological grade, and proliferation index (Ki-67). Differential microbial taxa were identified using the Wilcoxon signed-rank test and linear discriminant analysis effect size (LEfSe). Functional pathways were predicted using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Results: No significant differences in alpha or beta diversity were observed between the BC and NAT groups (P>0.05). The LEfSe revealed that Conclusions: Overall, microbial diversity was similar between the BC and NAT groups; however, distinct microbial profiles were identified in the BC tissue group and among the clinicopathological subgroups. Brevundimonas was the predominant genus in the H-Ki-67 group. This study provides novel insights and potential targets that may extend our understanding of BC-related microbial mechanisms and advance microbiota-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.